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Background: PGRMC1 (progesterone receptor membrane component 1) is a highly conserved heme binding
protein, which is overexpressed especially in hormone receptor-positive breast cancer and plays an important role
in breast carcinogenesis. Nevertheless, little is known about the mechanisms by which PGRMC1 drives tumor
progression. The aim of our study was to investigate the involvement of PGRMC1 in cholesterol metabolism to
detect new mechanisms by which PGRMC1 can increase lipid metabolism and alter cancer-related signaling
pathways leading to breast cancer progression.
Methods: The effect of PGRMC1 overexpression and silencing on cellular proliferation was examined in vitro and in
a xenograft mouse model.
Next, we investigated the interaction of PGRMC1 with enzymes involved in the cholesterol synthesis pathway such
as CYP51, FDFT1, and SCD1. Further, the impact of PGRMC1 expression on lipid levels and expression of enzymes
involved in lipid homeostasis was examined. Additionally, we assessed the role of PGRMC1 in key cancer-related
signaling pathways including EGFR/HER2 and ERα signaling.
Results: Overexpression of PGRMC1 resulted in significantly enhanced proliferation. PGRMC1 interacted with key
enzymes of the cholesterol synthesis pathway, alters the expression of proteins, and results in increased lipid levels.
PGRMC1 also influenced lipid raft formation leading to altered expression of growth receptors in membranes of
breast cancer cells. Analysis of activation of proteins revealed facilitated ERα and EGFR activation and downstream
signaling dependent on PGRMC1 overexpression in hormone receptor-positive breast cancer cells. Depletion of
cholesterol and fatty acids induced by statins reversed this growth benefit.
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Conclusion: PGRMC1 may mediate proliferation and progression of breast cancer cells potentially by altering lipid
metabolism and by activating key oncogenic signaling pathways, such as ERα expression and activation, as well as
EGFR signaling. Our present study underlines the potential of PGRMC1 as a target for anti-cancer therapy.
Keywords: PGRMC1, Breast cancer, Tumor progression, Cholesterol, Lipids, Estrogen receptor α, HER2, EGFR, Breast
cancer signaling pathwayBackground
With approximately 25% of all new cancer cases, breast
cancer is the most common cancer in women [1] and re-
sponsible for the highest fraction of cancer death [2].
Therefore, the investigation of underlying mechanisms
on molecular levels and the discovery of new therapy ap-
proaches are research goals of utmost significance.
Progesterone receptor membrane component 1
(PGRMC1) is a highly conserved protein, which is pri-
marily found in the liver and kidney but also expressed
in various tissues such as brain, breast, lung, pancreas,
and reproductive tissues [3–5].
PGRMC1 has been confirmed to play a role in carcino-
genesis especially in breast cancer and may therefore rep-
resent a target for cancer therapy [6]. In many studies,
upregulation of PGRMC1 protein and mRNA was de-
tected in malignancies including colon, lung, ovary, cervix,
and breast [7–11]. Besides, PGRMC1 expression correlates
with metastasis to lymph nodes, larger tumor size, and
poorer overall- and tumor-free survival [9, 12]. Further,
interactions of PGRMC1 or its homologous proteins with
cytochrome P450 enzymes (CYPs) have been reported, for
example by stably binding heme in its cytb5 related do-
main [3, 5, 13–15]. PGRMC1 leads to resistance against
chemotherapeutic agents like doxorubicin, cisplatin, and
paclitaxel [13, 16, 17]. Moreover, different authors discuss
an involvement of PGRMC1 in cholesterol synthesis via
interaction with CYPs [3, 5, 18]. The role of cholesterol in
cancer is still not fully evaluated. Many studies describe an
association of high plasma and endogenous cholesterol
levels with (breast) cancer development and progression
[19–21], pointing towards a major role in cancer. Elevated
cholesterol and steroid levels may affect carcinogenesis in
different ways, e.g., in saturating the increased require-
ment for membrane components due to abundant cell
growth [22]. Furthermore, high cholesterol levels result in
an increase in the size and number of lipid rafts. Since
lipid rafts contain several signaling molecules, differences
in lipid rafts are modulating signaling cascades [23, 24],
such as EGFR and HER2 signaling and expression [25]. In
addition, cholesterol is the precursor of steroid hormones
like estradiol (E2), the important growth factor for hor-
mone receptor-positive breast cancer [26].
The aim of the present study was to investigate the
impact of PGRMC1 on lipid metabolism, lipid raftformation, and its contribution to breast cancer progres-
sion and cancer-associated signaling pathways in hormone
receptor-positive (MCF7) and hormone receptor-negative
(MDA-MB-231) cells. For this purpose, interaction of
PGRMC1 with enzymes of the mevalonate pathway was
evaluated. Subsequently, effects of PGRMC1 expression
on cholesterol and lipid levels were investigated. A
special focus was placed on PGRMC1-dependent
expression and signaling of ERα and EGFR/HER2. To
explore the impact of modified lipid and steroid
metabolism (due to PGRMC1 expression), breast can-
cer cell growth was further explored by PGRMC1
overexpression and -silencing.Methods
Cells and cell culture
MCF7, T47D, and MDA-MB-231 cells were purchased
from the ATCC (Manassas, Virginia). Cells were main-
tained in RPMI 1640 medium (Thermo Fisher Scientific,
Waltham, Massachusetts), supplemented with 10% (v/v)
fetal bovine serum (Thermo Fisher Scientific, Waltham,
Massachusetts), 100 units/mL penicillin/streptomycin
(Thermo Fisher Scientific, Waltham, Massachusetts),
and 0.025 mol/L HEPES (Thermo Fisher Scientific, Wal-
tham, Massachusetts) in a humidified incubator at 37 °C
with 5% CO2. Cells (passage number ≤ 25) were authen-
ticated regularly by Microsynth AG (Balgach,
Switzerland) using STRS analysis. The last authentica-
tion was performed on May 22, 2018.Transfection of cell lines
Cells were transfected with the expression vector
pcDNA3.1/Hygro(+) (Thermo Fisher Scientific, Wal-
tham, Massachusetts), containing 3x HA-tagged (3x hu-
man influenza hemagglutinin-tagged) PGRMC1, using
Lipofectamine™ 2000 transfection reagent (Thermo
Fisher Scientific, Waltham, Massachusetts) (MCF7/
PGRMC1, T47D/PGRMC1 and MDA-MB-231/
PGRMC1). As a control, we used cells transfected with
the “empty” vector (MCF7/EVC, T47D/EVC, and MDA-
MB-231/EVC). Stable transfection was verified by PCR,
western blot, and immunofluorescence staining, to iso-
late PGRMC1-over-expressing clones.
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For silencing of endogenous PGRMC1 in MCF7 cells,
FlexiTube GeneSolution for PGRMC1 (Qiagen, Hilden,
Germany) was used, containing four siRNAs that specif-
ically target human PGRMC1 mRNA. Cells were har-
vested after cultivation for 24 h, 48 h, and 72 h at 37 °C
to verify silencing by western blot analysis.
For MTT assays, cells were pre-incubated with siRNA
against PGRMC1 for 24 h at 37 °C in cell culture flasks
to silence the endogenous protein. Subsequently, the
cells were seeded in 96-well plates and again treated
with siRNA. Cell viability was measured after 24 h, 48 h,
and 72 h at 37 °C of incubation.
MTT assay
Cells (5 × 104 cells per well) were seeded in triplicates in
96-well plates in complete medium. Cells were either
grown (for different timespans) in full medium without
or with treatment. Afterwards cells were incubated with
0.25 mg/ml MTT solution for 3 h. After 1 h of incuba-
tion with DMSO, absorption at 540 nm was determined
with TECAN Spark®.
Quantification of lathosterol and cholesterol
Cholesterol and lathosterol were quantified by gas
chromatography-mass spectrometry analysis as de-
scribed previously (Maier et al., 2009), with minor
modifications.
Western blot analysis
Samples for western blot analysis and the respective mo-
lecular weight marker were loaded onto Mini-
PROTEAN® Precast Gel and separated via SDS-Page at
150 V. We activated the PVDF membrane with metha-
nol. Transmission of proteins was performed for 16 h at
4 °C and 10mA in blotting buffer. Afterwards, unspecific
binding was blocked by incubation of the PVDF mem-
brane with the transferred proteins with blocking solu-
tion for 1 h at room temperature. Primary antibody in
respective concentration was added in blocking solution
and incubated for 16 h at 4 °C. Subsequently, a second-
ary antibody was applied in 20% blocking solution at
room temperature. Proteins were detected using Amer-
sham™ ECL™ Western Blotting Detection Reagent.
Co-immunoprecipitation
Immunoprecipitation of HA-tagged PGRMC1 and HA-
tagged PGRMC1-variants was performed using the
Pierce™ HA-Tag IP/Co-IP Kit according to the manufac-
turer’s instructions. Cells overexpressing GFP-tagged
PGRMC1 were used as a negative control. Cell pellets
were resuspended in Co-IP lysis buffer. An amount of
500-μg protein was incubated with anti-HA agarose
slurry at 4 °C overnight. For elution, proteins weredenatured in sample buffer at 95 °C for 5 min and the
eluent was supplemented with 1M DTT. The elution of
PGRMC1 and mutual interaction partners was analyzed
directly via mass spectrometry (explained in the supple-
ments), SDS-PAGE, and western blot.
Proximity ligation assay (PLA)
The PLA procedure was performed using the Duolink®
PLA Kit. Cells were grown in chamber slides. Incubation
with the primary antibody cocktail containing anti-
PGRMC1 antibody and antibody against one of the pos-
sible interaction partners (or rabbit isotype IgG as nega-
tive control) was performed overnight at 4 °C.
Additionally, staining with anti-cytokeratin antibody
for 1 h was performed after amplification. Afterwards,
cells were stained with DAPI for 10 min and analyzed by
fluorescence microscopy within 1 week.
Reverse phase protein array (RPPA)
RPPA using Zeptosens technology was used for analysis
of signaling protein expression and activity profiling.
RPPA assay images were analyzed using ZeptoVIEW
Pro 3.1 array analysis software. Sample signals were
quantified as protein-normalized, blank-corrected mean
fluorescence intensities (NFI) of the single spots applying
linear fits and interpolation to the mean of the four
printed sample dilutions (eight spots per sample).
qRT-PCR
RNA was isolated from a cell pellet of 0.5 × 106 cells
using the RNeasy Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s specifications.
Reverse transcription of RNA into cDNA was per-
formed with the Omniscript RT kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions.
For qPCR, QuantiFast SYBR Green PCR kit (Qiagen,
Hilden, Germany) and RT [2] qPCR Primer assays for
ESR1, HER2, TFF1, Myc, CCND1, PGR, SCD, FASN,
HMGS1, SREBF1, SREBF2, LDLR, ACAT1, and PDH
(Qiagen, Hilden, Germany) were used according to the
manufacturer’s specifications. qPCR was performed
using the LightCycler® 480 System (Roche, Penzberg,
Germany).
Estradiol ELISA
Supernatants of MCF7/EVC and MCF7/PGRMC1 cells
were analyzed for 17β-Estradiol (E2) concentrations
using a commercially available kit (ab108667, Abcam
plc, Cambridge, UK) according to the manufacturer’s
specifications.
Staining for lipid rafts and HER2
Co-staining of HER2 with lipid rafts was performed in
PGRMC1 overexpressing MCF7 and MDA-MB-231 cells
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seeded in a chamber slide for 24 h. Afterwards, the
medium was removed, and the cells were incubated for
another 24 h with medium containing stripped FCS and
were then incubated for 24 h with medium containing
normal FCS. Staining of lipid rafts was performed using
Vybrant™ Alexa Fluor™ 488 Lipid Raft Labeling Kit.
Afterwards, cells were fixed with 4% formaldehyde for
10 min. DAKO® protein block was used to block unspe-
cific binding sites for 1 h. Following this, cells were
stained with antibodies specific for HER2 (ab16901) over
night at 4 °C followed by an anti-mouse secondary-
antibody (Alexa Fluor 549 labeled) for 1 h. As negative
control mouse isotype IgG was used. After this, staining
with DAPI was performed. Subsequently cells were ex-
amined by fluorescence microscopy using Axioplan 2
Imaging (Carl Zeiss Microscopy GmbH, Jena, Germany).
For analyzing the amounts of lipid rafts and HER2 via
flow cytometry, cells were seeded in culture flasks and
synchronized as described above. Staining and fixation
was performed as described above. The emission (488
nm wavelength) was detected via high throughput flow
cytometry (CyAn, Beckman Coulter, Brea, USA).
Staining of lipid droplets
For visualizing of lipid droplets in PGRMC1 overex-
pressing MCF7, T47D, and MDA-MB-231 cells and
their respective empty vector controls via fluorescence
microscopy, the cells were grown in chamber slides for
24 h. Afterwards cells were stained with BODIPY™ 493/
503 (Sigma-Aldrich, St. Louis, Missouri) solubilized in
FCS-free medium and 2% BSA for 30 min. Cells were
fixed with 4% formaldehyde for 10 min, stained with
DAPI, and examined by fluorescence microscopy. For
analyzing amounts of lipid droplets via flow cytometry,
cells were grown for 24 h and harvested with trypsin.
Staining was performed as described above. The emis-
sion (488-nm wavelength) was detected via high
throughput flow cytometry (CyAn, Beckman Coulter,
Brea, USA).
Scatter plots of breast cancer microarray data
We obtained normalized microarray data (Affymetrix
Human Genome U133A Array) from the Gene Expres-
sion Omnibus (GEO, NCBI) [27]. The samples were nor-
malized using global scaling by the data set authors. We
confirmed the value distribution using mean values and
boxplots. Technical replicates were averaged. The values
of a selected panel of reporters were correlated against a
PGRMC1 reporter utilizing Spearman’s correlation.
Xenograft models
NOD.CB17-Prkdcscid (SCID) mice (female, 6-weeks old)
were obtained from the Jackson Laboratory (Bar Harbor,Maine) and were bred in the SPF animal facility of the
Institute of Genetics at the Biological Research Centre,
Szeged, Hungary. Young adult SCID female mice were
transplanted subcutaneously in the flank with 17β-
estradiol pellet (containing biodegradable carrier-binder,
1.7 mg/pellet, 60-day release; SE-121, Innovative Re-
search of America, Sarasota, Florida) under pentobar-
bital anesthesia. The next day, the mice were injected
subcutaneously with 3 × 106 tumor cells in the opposite
flank. The mice were checked daily, and the tumor size
was measured twice weekly. At the end of the experi-
ment, the animals were euthanized, by pentobarbital
overdose, and the tumors dissected.
Treatment with simvastatin
For treatment with simvastatin, cells (105 cells per well)
were seeded in 96-well plates in complete medium for
24 h/37 °C. Afterwards, the medium was removed and
the cells were incubated with 100, 50, 25, 12.5, 6.25, and
3.125 μg/mL simvastatin for MCF7 cells and 20, 10, 5,
2.5, 1.25, and 0.625 μg/mL simvastatin for MDA-MB-
231. MTT assays were performed after 24 h, 48 h, and
72 h.
Statistical analysis
All experiments were performed with several independ-
ent biological replicates and repeated a minimum of
three iterations. Results are reported as means with
standard deviation. The data were tested for normal dis-
tribution using Shapiro-Wilk and Kolmogorov-Smirnov
test. Differences between groups were determined by un-
paired Student’s t test. Statistical analysis was performed
using R (RStudio) and IBM SPSS. Spearman’s ρ was cal-
culated in R using normalized microarray data and was
plotted as a scatterplot using the ggpubr R library. p <
0.05 was considered as statistically significant.
Results
PGRMC1 promotes viability of breast cancer cells and
growth of xenograft tumors while PGRMC1 inhibition and
downregulation reduce viability of breast cancer cells
As already shown in previous studies by us and others,
PGRMC1 overexpression results in increased prolifera-
tion of tumor cells [28–30]. In accordance with these re-
sults, in our study, MCF7/PGRMC1 and T47D/
PGRMC1 cells also profit from a significantly higher via-
bility compared to the respective empty vector control
cells (Fig. 1b, supplemental Figure 1A). For MDA-MB-
231 cells overexpressing PGRMC1, no such effects can
be observed (Fig. 1b). To further strengthen our theory,
we examined the impact of PGRMC1 silencing on tumor
proliferation by knocking down endogenous PGRMC1
expression. As hypothesized, the knockdown of PGRMC1
led to significantly decreased viability of MCF7 and T47D
Fig. 1 a Cell viability of MCF7/EVC and MCF7/PGRMC1 cells as well as MDA-MB-231/EVC and MDA-MB-231/PGRMC1 cells (n = 3). Viability was
analyzed by MTT assay at t = 0 h, 24 h, 48 h, 72 h, and 96 h/37 °C. Values were normalized to t = 0 (100%). *p≤ 0.05, **p≤ 0.01 (Student’s t test, n =
3). b Cell viability of MCF7 and MDA-MB-231 cells, treated with siRNA against PGRMC1 (siPGRMC1) and scrambled siRNA (siControl) (Student’s t
test, n = 3). Viability was analyzed at t = 0 h, 24 h, 48 h, and 72 h/37 °C. Values were normalized to t = 0 (100%). *p ≤ 0.05, **p≤ 0.01 (Student’s t
test, n = 3). c Tumor volumes of immunodeficient mice bearing human breast cancer MCF7/EVC and MCF7/PGRMC1 xenografts. ***p≤ 0.001,
****p≤ 0.0001 (Student’s t test, n = 11 mice each group). Images of tumor tissue dissected from each mouse
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Figure 1B).
To validate and strengthen the in vivo findings of
Ruan et al. [30], to verify “our” cell models but also to
extend the data to other ER-positive BC cells, weinvestigated effects of PGRMC1 overexpression on
MCF7 and T47D breast cancer cell growth in a xeno-
graft model. On that account, MCF7/PGRMC1 and
T47D/PGRMC1 cells were injected into the flanks of im-
munodeficient mice. As control, we used EVC cells.
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measured. As assumed, mice injected with PGRMC1
overexpressing breast cancer cells matured significantly
larger tumor masses, than mice injected with the re-
spective EVC cells (Fig. 1c, supplemental Figure 1C).
PGRMC1 interacts with proteins of the mevalonate
pathway
As already shown in previous studies from different re-
search groups, PGRMC1 might regulate cholesterol syn-
thesis in different ways, e.g., by activating enzymes of the
mevalonate pathway like CYP51/lanosterol demethylase
or by binding to the proteins Insig and Scap, which span
the endoplasmic reticulum and sense cholesterol levels
[31, 32]. In our present study, we focused on this regu-
lating influence and its possible involvement in PGRM
C1-induced breast cancer promotion.
In order to get a broader view about the role of PGRM
C1 in this context, we screened for potential PGRMC1
interaction partners by mass spectrometry analysis of
proteins co-immunoprecipitated from whole cell lysates
of MCF7 cells that had been transfected with PGRMC1-
HA, utilizing an antibody directed against the HA-tag
(Fig. 2a). Among proteins with higher significance, we
found various potential interaction partners involved in
the mevalonate pathway (e.g., SCD1, FDFT1, and
CYP51A1) and cellular transport processes such as
vesicle trafficking (e.g., Coatomer subunit beta and Coat-
omer subunit gamma-1) and nuclear export or import
(e.g., Exportin-1, Exportin-2, Exportin-5, Exportin-7 or
Importin-4 and Importin-5) processes. Since SCD1,
FDFT1, and CYP51A1 indicate a high evidence for pro-
tein interaction with PGRMC1 and since they play an
important role in cholesterol metabolism, we scrutinized
these interactions. Interaction of PGRMC1 with SCD1,
FDFT1, and CYP51A1 was confirmed by immunopreci-
pitating PGRMC1-HA in MCF7/PGRMC1 cells and by
subsequently visualizing the respective interaction part-
ners via western blot (Fig. 2b). To verify the observed in-
teractions in different cell lines independently of PGRM
C1 overexpression and immunoprecipitation, we per-
formed proximity ligation assay of candidate proteins
with endogenous PGRMC1 in MCF7 (Fig. 2c) and
MDA-MB-231 cells (supplemental Figure 1B). Interac-
tions between PGRMC1 and the respective enzymes are
represented by single spots in fluorescence microscopy.
While in MCF7 cells, a high number of spots per cell
were visible for the interaction with CYP51, FDFT1, and
SCD1, the low number of spots in MDA-MB-231 cells
indicated no or little interaction (Fig. 2d). Interactions of
PGRMC1 with FDFT1 and SCD1 were also observed in
T47D cells (supplemental Figure 2B,C). Western blot
analysis of protein expression of SCD1, FDFT1, and
CYP51 revealed higher CYP51 and SCD1 protein levelsin MCF7/PGRMC1 cells compared to MCF7/EVC, while
no difference in MDA-MB-231/PGRMC1 cells could be
observed compared to MDA-MB-231/EVC cells (Fig. 2e).
These results implicate not only a direct interaction of
PGRMC1 with SCD1, FDFT1, and CYP51, but also an
increased PGRMC1-driven upregulation of these en-
zymes in estrogen receptor-positive cells, that appeared
absent in hormone receptor-negative cells.
Overexpression of PGRMC1 leads to higher levels of
cholesterol in hormone receptor-positive breast cancer
cells
We hypothesized that the interaction of PGRMC1 with
enzymes of the mevalonate pathway might alter their
function and thus affects cholesterol synthesis, resulting
in elevated cholesterol levels, which may provide energy
and components supporting cancer metabolism. There-
fore, we measured intracellular cholesterol levels in syn-
chronized PGRMC1 overexpressing and empty vector
control MCF7 and MDA-MB-231 cells via mass spec-
trometry (Fig. 2f). Overexpression of PGRMC1 in MCF7
cells caused a significant increase (p < 0.05) of intracellu-
lar cholesterol levels compared to the empty vector con-
trol, while no difference in MDA-MB-231/PGRMC1
cells was observed (Fig. 2f). Additionally, levels of lathos-
terol, a precursor of cholesterol, were measured (Fig. 2f).
For MCF7/PGRMC1 cells, we detected a significantly
decreased ratio compared to MCF7/EVC cells. Interest-
ingly, a significantly decreased ratio of lathosterol/chol-
esterol in MDA-MB-231/PGRMC1 cells was observed
compared to MDA-MB-231/EVC cells, pointing towards
a small influence of PGRMC1 on cholesterol de novo
synthesis in these cells. The data reveal an impact of
PGRMC1 on de novo synthesis of cholesterol regarding
cholesterol levels and enzymatic turnover.
Upregulation of ERα, ERα downstream targets, and E2
levels mediated by PGRMC1
Since cholesterol is the precursor for steroid hormones,
we assumed that enhanced cholesterol synthesis may
affect E2 levels. E2 plays an essential role in hormone
receptor-positive breast cancer, e.g., by activating ERα
which is leading to tumor proliferation. E2 levels were
determined in the supernatant of MCF7/PGRMC1 cells
by ELISA (Fig. 3a). Consistent with the higher amounts
of cholesterol in MCF7/PGRMC1 cells, we found signifi-
cantly increased levels of E2 in the supernatant of
MCF7/PGRMC1 cells in comparison to MCF7/EVC
cells. To analyze the effect of higher E2 levels in MCF7/
PGRMC1 cells on breast cancer signaling, we deter-
mined the expression of different proteins known to play
a role in key signaling cascades in breast cancer via re-
verse phase protein array technology (RPPA) (Fig. 3b).
RPPA analysis revealed significantly (p < 0.05) elevated
Fig. 2 a Scatter plot of proteins with significantly higher intensities in PGRMC1-HA samples compared to PGRMC1-GFP samples identified by
mass spectrometry. The most significant proteins exhibit very high value for Student’s t test difference HA_GFP and –log Student’s t test p value
HA_GFP and are found in the upper right corner. Highlighted are proteins with important functions in steroid synthesis. b Detection of co-
immunoprecipitated proteins CYP51A1, Stearoyl-CoA desaturase (SCD1), and FDFT1 by western blot. c Verification of the interactions via proximity
ligation assay. Quantification of dots per cell. d Visualization via immunofluorescence microscopy. e Quantification of protein expression of CYP51,
SCD1, and FDFT1 in MCF7/PGRMC1 cells and MDA-MB-231/PGRMC1 cells compared to their respective empty vector control by western blot.
*p≤ 0.05, ***p ≤ 0.001. f Detection of cholesterol and its precursor lathosterol in PGRMC1 overexpressing cells compared to the empty vector
control cells with mass spectrometry *p≤ 0.05, ***p ≤ 0.001 (Student’s t test, n = 3)
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MCF7/EVC cells (Fig. 3b). Subsequently higher levels of
HER2 and c-Myc proteins, whose expression depend on
the transcriptional activity of ERα, were observed while
c-Fos and PR levels were not altered (Fig. 3b). To verify
the results from RPPA, western blots were performed to
detect protein expression of ERα, HER2, and c-Myc
(Fig. 3c). In MCF7/PGRMC1 cells, expression of ERα,
HER2, and c-Myc is increased. Because E2 activates ERα
and our previous studies have demonstrated higher E2levels in MCF7/PGRMC1 cells compared to MCF7/EVC
(Fig. 3a), we analyzed ERα phosphorylation at S118
(ERα-P-S118), which was also significantly increased
(p < 0.01) in MCF7/PGRMC1 cells compared to MCF7/
EVC (Fig. 3c). Additionally, we performed qPCR analysis
of mRNA expression for ESR1, Tff1, HER2, CCND1,
Myc, and PGR in the PGRMC1 overexpressing cell lines
in comparison to the empty vector control (Fig. 3d, sup-
plemental Figure 3B). In MCF7/PGRMC1 and T47D/
PGRMC1 we detected higher mRNA levels for ESR1 and
Fig. 3 a Amount of E2 in the supernatant of MCF7/PGRMC1 cells compared to the empty vector control after 48 h, detected with ELISA. **p ≤
0.01. b NFI (blank-corrected mean fluorescence intensity) ratio of protein expression of ERα, Her2, PR, c-Myc, and c-Fos analyzed by RPPA. Protein
expression was normalized to MCF7/EVC and protein expression measured in MCF7/EVC cells was set to 1. Up-/downregulation of protein
expression in MCF7/PGRMC1 cells were calculated. *p≤ 0.05 (Student’s t test, n = 3). c Western blot analysis of ERα, Her2, and c-Myc protein levels
in MCF7/EVC and MCF7/PGRMC1 cells. Representative picture of 3 independent analyses. d qRT-PCR analysis of ESR1, TFF1, HER2, CCND1, Myc, and
PGR mRNA expression in MCF7/EVC and MCF7/PGRMC1 cells, MDA-MB-231/EVC and MDA-MB-231/PGRMC1 cells. *p≤ 0.05, ***p≤ 0.001 (Student’s
t test, n = 3). e qRT-PCR analysis of PGRMC1, ESR1, HER2, and TFF1 mRNA expression in MCF7 siCtrl and MCF7 siPGRMC1 cells. *p≤ 0.05, **p < 0.01,
****p≤ 0.0001 (Student’s t test, n = 3). f Western blot analysis of ERα and Her2 protein levels in MCF7 siCtrl and MCF7 siPGRMC1 cells.
Representative blot from 3 independent analyses. g Quantification of HER2 protein in membranes of unpermeabilized MCF7/EVC and MCF7/
PGRMC1 cells, MDA-MB-231/EVC and MDA-MB-231/PGRMC1 cells, and MCF7 siCtrl and MCF7 siPGRMC1 cells (h) via flow cytometry. *p≤ 0.05
(Student’s t test, n = 3)
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and Myc as reporter genes for ERα activation compared
to MCF7/EVC and T47D/EVC. Interestingly, mRNA
levels of PGR were significantly lower in the PGRMC1overexpressing cells compared to their empty vector
control. To further consolidate our hypothesis, we sig-
nificantly silenced (p < 0.01) PGRMC1 expression by
siPGRMC1 (Fig. 3e). As expected, the expression of ERα,
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albeit no significant upregulation was detected for
mRNA levels of HER2 pointing towards a post-
transcriptional regulation of HER2 levels by PGRMC1
(Fig. 3e). In accordance, western blot analysis revealed
decreased expression of ERα and HER2 in MCF7/
siPGRMC1 (Fig. 3f). Previous studies revealed that
HER2 overexpression causes deformation of the cell
membrane and a subsequent disruption of epithelial fea-
tures independent of receptor signaling [25, 33]. We
demonstrated higher HER2 expression on the surface of
non-permeabilized MCF7/PGRMC1 cells compared to
MCF7/EVC cells using flow cytometry (Fig. 3g). Simi-
larly, HER2 levels were reduced on the surface of
MCF7/siPGRMC1 cells (Fig. 3h). MDA-MB-231/
PGRMC1 cells even showed lower expression of HER2
compared to MDA-MB-231/EVC cells (Fig. 3g).
PGRMC1 overexpressing breast cancer cells show higher
amounts of neutral lipids and lipid droplets
Lipid droplets recently emerged as new organelles not
only due to their role in energy storage, but also as mod-
ulators of cell signaling and lipid homeostasis in several
diseases including breast cancer [34–36].
By altering cholesterol levels in breast cancer cells,
PGRMC1 could have a major influence on tumor growth
via an enhanced lipid droplet formation in hormone
receptor-positive breast cancer. To quantify the amount
of neutral lipids, PGRMC1 overexpressing cell lines and
their respective empty vector control were examined by
BODIPY® staining of neutral lipids respectively lipid
droplets. Subsequent flow cytometry analysis showed
that PGRMC1 overexpressing hormone receptor-
positive cells have a significantly higher amount of neu-
tral lipids in comparison to the empty vector control
(Fig. 4a, supplemental Figure 4A). Interestingly, we
found significantly lower levels of lipids in MDA-MB-
231/PGRMC1 cells compared to MDA-MB-231/EVC
(Fig. 4a). Our results point towards an upregulation of
lipid synthesis due to PGRMC1 overexpression in hor-
mone receptor-positive breast cancer, which might lead
to enhanced tumor growth.
PGRMC1 fuels endogenous lipid synthesis and lipid
uptake and upregulates enzymes of the cholesterol
metabolism
Besides the direct interaction of PGRMC1 with enzymes
of the mevalonate pathway, the influence of PGRMC1
on lipid metabolism might be explained by increased
mRNA expression of enzymes involved in endogenous
and exogenous lipid metabolism.
Quantitative PCR analysis revealed increased levels of
mRNA for SREBF1, SREBF2, LDLR, HMGS1, SCD,
FASN, and ACAT1 in MCF7/PGRMC1 cells comparedto MCF7/EVC cells (Fig. 4b, supplemental Figure 4B).
These enzymes are not only key players in cholesterol
and fatty acid synthesis, but also upregulated in breast
cancer and they are associated with a worse outcome. In
MDA-MB-231 cells, PGRMC1 overexpression did not
result in higher expression of the abovementioned pro-
teins (Fig. 4b). To show the increasing effect of PGRM
C1 on expression of enzymes of the lipid metabolism,
we obtained normalized microarray data of 63 hormone
receptor-positive breast cancers tissue samples [37].
Spearman’s correlation between the PGMRC1 expres-
sion level and various expression levels of proteins
(FASN, FDFT1, HMGCS1, HMGCR, LDLR, SCD) indi-
cated positive correlations between PGRMC1 and the re-
spective enzymes in luminal A breast cancer tissue
samples (Fig. 4c). Our findings advert to a complex and
diverse impact of PGRMC1 on lipid homeostasis in
breast cancer.
PGRMC1 enhances expression of lipid rafts in cell
membranes of breast cancer cells
Lipid rafts are cholesterol-rich microdomains in cell
membranes, which have functions in cell proliferation
and growth, membrane trafficking, metastasis, and apop-
tosis [23, 24, 38]. Furthermore, lipid raft formation in
cell membranes is influenced by FDFT1 activity [39].
Since lipid rafts play a role in breast cancer progression
and due to the fact that (a) PGRMC1 overexpressing
hormone receptor-positive breast cancer cells have
higher amounts of cholesterol and that (b) PGRMC1 in-
teracts with FDFT1, we determined the abundance of
lipid rafts in MCF7 and MDA-MB-231 cells with PGRM
C1 overexpression and respective empty vector control
as well as in MCF7 cells treated with siRNAs directed
against PGRMC1, to knockdown PGRMC1 (Fig. 4d).
Cells were stained with Vybrant™ Alexa Fluor™ 488 Lipid
Raft Labeling Kit and detected by flow cytometry.
MCF7/PGRMC1 cells showed significantly higher levels
of lipid rafts compared to the respective empty vector
control (Fig. 4d, upper). In addition, we found signifi-
cantly lower expression of lipid rafts when endogenous
PGRMC1 was knocked down in MCF7 cells (Fig. 4d,
lower). Interestingly, lipid rafts were decreased in PGRM
C1 overexpressing MDA-MB-231 cells (Fig. 4d).
Elevated proliferation mediated by lipid rafts is, among
others, attributed to modulation of signaling functions of
growth factor receptors like the ErbB (HER) receptor
family.
Since we found higher expression of HER2 in the
membrane of PGRMC1 overexpressing MCF7 cells
(Fig. 3g), we analyzed the HER2 expression in lipid rafts
in more detail.
PGRMC1 overexpressing MCF7 and MDA-MB-231
cells and respective empty vector control cells were co-
Fig. 4 a Detection of neutral lipids and lipid droplets in MCF7/EVC and MCF7/PGRMC1, MDA-MB-231/EVC and MDA-MB-231/PGRMC1 cells by
BODIPY® staining and quantification via flow cytometry. *p≤ 0.05, **p≤ 0.01. (Student’s t test, n = 3). b qRT-PCR analysis of SREBF1, SREBF2, LDLR,
HMGS1, SCD, FASN, ACAT mRNA expression in MCF7/PGRMC1 and MDA-MB-231/PGRMC1 cells compared to the respective EVC cells. *p≤ 0.05,
**p≤ 0.01, ***p≤ 0.001 (Student’s t test, n = 3). c Spearman’s correlation between the PGMRC1 expression level and various expression levels of
proteins (FASN, FDFT1, HMGCS1, HMGCR, LDLR, SCD) involved in lipid metabolism. Data obtained from normalized microarray data (Affymetrix
Human Genome U133A Array) of 63 hormone receptor-positive breast cancer tissue samples. d Detection of lipid rafts in cell membranes of
MCF7/EVC and MCF7/PGRMC1 cells, MDA-MB-231/EVC and MDA-MB-231/PGRMC1 cells, and MCF7 siCtrl and MCF7 siPGRMC1 cells by Vybrant™
Alexa Fluor™ 488 and subsequent quantification via flow cytometry. *p≤ 0.05, **p≤ 0.01 (Student’s t test, n = 3). e Immunofluorescence staining
with Vybrant™ Alexa Fluor™ 488, fluorescence immunocytochemistry for HER2, and nuclear staining with DAPI. 63-fold magnification. Cells were
grown on chamber slides for 24 h
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Figure 3C). Especially in MCF7/PGRMC1 cells, we
found a strong co-localization of HER2 in lipid rafts
(Fig. 4e).PGRMC1 influences activation of EGFR signaling
Another important member of the ErbB receptor family,
which plays a major role in breast cancer signaling, is
the EGFR. Several studies suggest that PGRMC1 may
promote EGFR phosphorylation and activation [8, 9, 13,
40]. The hypothesis of PGRMC1 enhancing EGFR sig-
naling was investigated by reverse phase protein array
(RPPA) with a focus on phosphorylation of EGFR and
its downstream targets in MCF7/PGRMC1 and MCF7/
EVC cells (Fig. 5a). Our results point towards an in-
creased phosphorylation of EGFR (p-Tyr1068), Akt (p-
Ser473 and p-Thr308), MEK1/2 (p-Ser217/Ser221),
ERK1/2 (p-Thr202/Tyr204), and S6 (p-Ser240/Ser244)
in PGRMC1/MCF7 cells compared to EVC cells (Fig. 5a).
In combination with our results from immunofluores-
cence staining, this suggests that there might exist a
powerful link between PGRMC1 expression and activa-
tion of oncogenic signaling pathways in MCF7 cells
(Fig. 5c).
To verify the RPPA results, we performed western blot
analysis of EGFR signaling induced with EGF (Fig. 5b).
Phosphorylation of EGFR, Akt, MEK1/2, and ERK1/2
was observed (Fig. 5b). Compatible, significantly elevated
levels of EGFR (p-Tyr1068), Akt (p-Ser473), MEK1/2 (p-
Ser217/Ser221), and ERK1/2 (p-Thr202/Tyr204) were
monitored in MCF7/PGRMC1 cells. In contrast, expres-
sion levels of total protein did not vary significantly
(Fig. 5c). MDA-MB-231 showed no difference in expres-
sion levels of EGFR (p-Tyr1068), Akt (p-Ser473), MEK1/
2 (p-Ser217/Ser221), and ERK1/2 (p-Thr202/Tyr204),
suggesting a subordinated role of PGRMC1 in EGFR sig-
naling in triple-negative breast cancer (supplemental Fig-
ure 4A, 4B).Cholesterol and fatty acid depletion induced by statins
reverses the growth benefit interceded by PGRMC1
Our findings suggest a complex and broad role of
PGRMC1 in cholesterol and lipid metabolism (Fig. 5d).
Based on our research concerning the influence of
PGRMC1 on lipid homeostasis and increased viability of
PGRMC1 overexpressing cells, we hypothesized that a
higher lipid synthesis might lead to a survival benefit of
PGRMC1 overexpressing cells.
To verify this hypothesis, we treated PGRMC1 overex-
pressing MCF7 and MDA-MB-231 cells and the respect-
ive controls with different concentrations of simvastatin,
a competitive inhibitor of HMG-CoA reductase, and
performed subsequent viability assays (Fig. 5d).Interestingly, contrary to expectations, inhibition of
HMG-CoA reductase and following depletion of choles-
terol not only assimilated viability in MCF7/PGRMC1
cells compared to MCF7/EVC cells, but even led to in-
ferior viability. This suggests a higher dependence of
PGRMC1 overexpressing cells on cholesterol. Intri-
guingly, MDA-MB-231 cells with PGRMC1 overexpres-
sion reacted similar to MCF7 cells (Fig. 5d).
Discussion
Although previous studies report on the proliferative ef-
fect of PGRMC1 in breast cancer, little is known about
the mechanisms by which PGRMC1 effects carcinogen-
esis. Therefore, our present study focuses on the modify-
ing function of PGRMC1 on lipid metabolism and
oncogenic signaling. Evidence is pointing towards a
meaningful impact of modified lipid metabolism in
breast cancer progression and metastasis [41–44]. Al-
though one of the most relevant mechanisms of energy
usage of cancer cells is their increase in glucose uptake
and their use of non-oxidative glycolysis, also known as
Warburg effect, breast cancer cells upregulate lipid de
novo synthesis and the uptake of free fatty acids and
low-density lipoproteins [44, 45]. Our findings suggest
the function of PGRMC1 as an important enhancer es-
pecially of lipid synthesis resulting in oncogenic signal-
ing and tumor progression. For the first time, we
detected enhanced mRNA expression of proteins regu-
lating lipid synthesis and uptake in PGRMC1 overex-
pressing hormone receptor-positive MCF7 and T47D
cells resulting in significantly higher lipid levels in
MCF7/PGRMC1 and T47D/PGRMC1 cells compared to
the empty vector control cells. Further, we could dem-
onstrate that PGRMC1 interacts with CYP51, FDFT1,
and SCD1, which are major players in lipogenesis. Inter-
estingly, these interactions are less pronounced in
MDA-MB-231 cells. An explanation for the lower inter-
action might be that triple-negative breast cancer cells
have been reported to cover their needs for lipids via the
uptake of exogenous fatty acids in contrast to perform-
ing lipid de novo synthesis [44, 46].
A possible result of the detected interactions between
PGRMC1 and CYP51, FDFT1, and SCD1 could be the
increase of cholesterol and neutral lipid levels in MCF7/
PGRMC1 and T47D/PGRMC1 cells. Since cholesterol is
the precursor of steroid hormones like estradiol, elevated
levels of cholesterol may subsequently lead to higher
levels of estradiol as indicated by our measurements in
the supernatant of MCF7/PGRMC1 cells of this sce-
nario. One consequence could be that PGRMC1 pro-
motes tumor progression by upregulation of ERα
protein and ESR1 mRNA directly via a transcriptional
mechanism or indirectly via elevated steroid synthesis.
Since various studies showed an upregulation of steady-
Fig. 5 (See legend on next page.)
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Fig. 5 a Protein phosphorylation of EGFR P-Tyr1068, Akt P-Ser473, Akt P-Thr308, MEK1/2 P-Ser217/Ser221, Erk1/2 P-Thr202/Tyr204, and S6 P-
Ser240/Ser244 analyzed by RPPA. NFI (blank-corrected mean fluorescence intensity) ratio of phospho-protein/total protein was calculated,
normalized to MCF7/EVC, and ratio in MCF7/EVC cells was set to 1. Up-/downregulation of protein phosphorylation in MCF7/PGRMC1 cells was
calculated. *p≤ 0.05, **p≤ 0.01 (Student’s t test, n = 3). b Protein phosphorylation of EGFR P-Tyr1068, Akt P-Ser473, MEK1/2 P-Ser217/Ser221, and
Erk1/2 P-Thr202/Tyr204 verified by western blot analysis. Cells were treated with EGF (10 ng/mL) for 10 min/37 °C. Representative blot of 3
independent analyses. Total protein expression of EGFR, Akt, MEK1/2, and Erk1/2 verified by western blot analysis. Representative blot of 3
independent analyses shown. c PGRMC1 mediates phosphorylation of EGFR and its downstream targets and upregulates E2 levels, ERα
expression, and ERα-target genes. EGFR phosphorylation activates the MAPK signaling cascade (including MEK1/2-, ERK1/2-, and S6-
phosphorylation) and PI3K signaling cascade (including Akt- and S6-phosphorylation). Phosphorylation of S6 induces transcription of genes,
involved in the regulation of cell cycle progression, cell proliferation, and glucose homeostasis. ERα translocates into the nucleus upon ligand-
dependent or ligand-independent activation and acts as a transcription factor to transcribe genes involved in tumor progression. d Overview of
the influence of PGRMC1 in cholesterol and lipid metabolism. e MCF7/EVC and MCF7/PGRMC1 cells were treated with 100 μM, 50 μM, 25 μM,
12.5 μM, 6.25 μM, and 3.175 μM simvastatin and respective DMSO control. MDA-MB-231/EVC and MDA-MB-231/PGRMC1 cells were treated with
20 μM, 10 μM, 5 μM, 2.5 μM, 1.25 μm, and 0.625 μM simvastatin and respective DMSO control. Viability was analyzed by MTT assay at t = 24 h, t =
48 h, t = 72 h and 37 °C. Depicted are results after 48 h of treatment. Viability is normalized on the DMSO control. p values were adjusted using
the Bonferroni correction (ndoses = 6; nreplicates = 9)
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creased levels of ERα plus a simultaneous autocrine/
paracrine activation by E2 may trigger a proliferative
cycle support in tumor growth. For the first time, we
also observed that PGRMC1 impacts on lipid rafts,
another regulator of cancer progression. Lipid rafts
are important, e.g., in modulation of membrane
geometry, lateral movement of molecules, and signal
transduction [23, 48]. We observed increased lipid
raft formation in PGRMC1 overexpressing hormone
receptor-positive breast cancer cells. The co-
localization of HER2 in lipid rafts, also reported by
other research groups [49, 50], may influence EGFR
signaling. Zhuang et al. reported an EGF-induced and
constitutive signaling via the Akt serine-threonine
kinase and subsequent survival in cancer cells [51].
Furthermore, EGFR and HER2 localization in lipid
rafts is discussed to play a role in cancer cell drug resist-
ance, e.g., regarding treatment with trastuzumab or tyro-
sine kinase inhibitors [49, 50]. On the other hand, Orr
et al. showed that altered cholesterol levels modify the
mobility of EGFR in the cell membrane leading to its de-
creased activation due to reduced dimerization of EGFR
monomeres [25]. The relevant role of PGRMC1 in pro-
moting phosphorylation and activation of receptors for ex-
ample by heme-dependent PGRMC1 dimerization has
already been reported [8, 9, 13, 40]. Here, elevated phos-
phorylation levels of EGFR and its downstream targets in
MCF7/PGRMC1 cells were discovered. The crosstalk be-
tween EGFR/Her2 and ERα signaling cascades has often
been reported, whereby ERα can induce the E2-dependent
activation of the EGFR signaling pathway by promoting
phosphorylation of Akt (P-Ser473) via the non-genomic
pathway. Alternatively, ERα activation can be accom-
plished independently of estrogens by EGFR-activated
MAPK-signaling or PI3K pathway [52, 53]. In the current
study, we demonstrate that both MAPK and PI3K path-
way components (i.e., MEK1/2, ERK1/2, and AKT) areactivated in PGRMC1 overexpressing MCF7 cells. This
may lead to increased ERα activation and finally to in-
creased cancer proliferation. Additionally, ERα and HER2
correlate positively in HER2 non-overexpressing breast
cancer [54, 55]. Hence, higher levels of ER in MCF7/
PGRMC1 cells could lead to higher expression of HER2.
However, the influence of PGRMC1 on EGFR/HER2 sig-
naling in lipid rafts and its impact on tumor progression
requires further studies.
Due to the role of the mevalonate pathway and its dual
role in cholesterol synthesis and prenylation of signaling
proteins, statins have been tested as anti-cancer drugs.
Statins block the HMG-CoA reductase, the gatekeeper of
the mevalonate pathway. We speculated due to increased
activation of the mevalonate pathway and due to higher
cholesterol and neutral lipids production that PGRMC1
overexpressing cells may be more dependent on the meva-
lonate pathway. Hence, they might be more susceptible to
statin treatment [56–60]. For the first time, we detected
that MCF7/PGRMC1 and MDA-MB-231/PGRMC1 cells
are more sensitive to treatment with simvastatin com-
pared to the respective controls. We assume that PGRM
C1 overexpression leads to higher dependence on choles-
terol and fatty acids of cancer cells due to an alteration of
fatty acid metabolism, by enhanced driving of the mevalo-
nate pathway and related synthesis of the isoprenoids ger-
anylgeranyl pyrophosphate (GGPP) and farnesyl
pyrophosphate (FPP) [61, 62], e.g., leading to inhibition of
small Rho GTPase prenylation [63].
Indeed, PGRMC1 might also reduce viability of breast
cancer cells under treatment with statins, because
PGRMC1 is known to interact with CYP enzymes [3, 5,
13–15]. Specifically, inhibition of cytochromes P450
could increase the concentration of simvastatin, since
statins are metabolized by CYP3A4.
Hence, PGRMC1 overexpressing tumors may be an in-
teresting target for additional cholesterol lowering
therapy.
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We demonstrate that PGRMC1 mediates progression of
breast cancer cells potentially by altering cholesterol and
lipid metabolism and activating key drivers of tumor
progression in breast cancer, namely ERα expression
and activation, as well as EGFR signaling. Our data
underline the contribution of PGRMC1 to especially
hormone receptor-positive breast cancer pathogenesis
in vitro and in vivo and suggest its potential as a target
for anti-cancer therapy.
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